News:EMBL Course: Circulating Tumour DNA in Clinical Applications
Entering edit mode
3.9 years ago

Course Overview

Minimally invasive liquid biopsies have recently emerged as novel diagnostic methods which hold the promise to monitor disease progression, detect minimal residual disease, therapy resistance and potentially even early cancer detection. Participants will gain hands-on experience in the detection of cell free tumor DNA (cfDNA) using a next generation sequencing (NGS) approach that covers all four mutation classes in a single assay. Critical aspects on recent developments to increase analytical sensitivity and mitigate sequencing errors (computational error correction) will be discussed as well as annotation, interpretation, and clinical reporting of liquid biopsy tests. Lectures will cover the evaluation of ctDNA as biomarkers, clinical applications, emerging analytes for liquid biopsy and important challenges.

LOCATION & DATES EMBL Advanced Training Centre Heidelberg, Germany 9 - 12 Mar 2020


Liquid-biopsy Clinical-application Tumour-cells • 681 views

Login before adding your answer.

Traffic: 1456 users visited in the last hour
Help About
Access RSS

Use of this site constitutes acceptance of our User Agreement and Privacy Policy.

Powered by the version 2.3.6